Supernus Pharmaceuticals, Inc. (SUPN): Price and Financial Metrics

SUPN POWR Grades

• SUPN scores best on the Value dimension, with a Value rank ahead of 93.02% of US stocks.
• SUPN's strongest trending metric is Momentum; it's been moving up over the last 177 days.
• SUPN's current lowest rank is in the Sentiment metric (where it is better than 15.4% of US stocks).

SUPN Stock Summary

• SUPN's current price/earnings ratio is 32.04, which is higher than 78.99% of US stocks with positive earnings.
• In terms of twelve month growth in earnings before interest and taxes, SUPERNUS PHARMACEUTICALS INC is reporting a growth rate of -29.8%; that's higher than 31.22% of US stocks.
• In terms of volatility of its share price, SUPN is more volatile than 28.93% of stocks we're observing.
• If you're looking for stocks that are quantitatively similar to SUPERNUS PHARMACEUTICALS INC, a group of peers worth examining would be NUVA, SMLR, ZEV, DHX, and EVRI.
• Visit SUPN's SEC page to see the company's official filings. To visit the company's web site, go to www.supernus.com.

SUPN Valuation Summary

• In comparison to the median Healthcare stock, SUPN's price/sales ratio is 52.63% higher, now standing at 2.9.
• Over the past 133 months, SUPN's price/earnings ratio has gone up 29.3.

Below are key valuation metrics over time for SUPN.

SUPN Growth Metrics

Its 2 year cash and equivalents growth rate is now at -48.75%.
• Its 4 year revenue growth rate is now at 76.13%.
• Its 3 year net cashflow from operations growth rate is now at -29.38%.

SUPN's revenue has moved up $266,205,000 over the prior 33 months.

The table below shows SUPN's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	658.96	138.025	37.672
2022-06-30	630.071	120.074	57.485
2022-03-31	601.349	95.229	73.346
2021-12-31	579.775	127.127	53.424
2021-09-30	564.282	110.297	81.75
2021-06-30	570.953	120.006	100.185

SUPN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• SUPN has a Quality Grade of B, ranking ahead of 91.1% of graded US stocks.
• SUPN's asset turnover comes in at 0.375 -- ranking 128th of 682 Pharmaceutical Products stocks.
• RETA, INVA, and PTCT are the stocks whose asset turnover ratios are most correlated with SUPN.

The table below shows SUPN's key quality metrics over time.